Synlogic announces initiation of synpheny-3 global, pivotal phase 3 study evaluating synb1934 for treatment of phenylketonuria

Registrational study designed to support bla submission of first-in-class biotherapeutic company further streamlining organization to focus resources on execution of late clinical-stage programs in rare metabolic diseases cambridge, mass., june 05, 2023 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the initiation of synpheny-3, a global, pivotal phase 3 study evaluating the efficacy and safety of synb1934 as a potential treatment for phenylketonuria (pku).
SYBX Ratings Summary
SYBX Quant Ranking